<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463150</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-7</org_study_id>
    <nct_id>NCT01463150</nct_id>
  </id_info>
  <brief_title>Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing &lt;60 kg Post Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing &lt;60 kg Post Percutaneous Coronary Intervention (PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of dual antiplatelet therapy is considered standard of care in patients post
      percutaneous coronary intervention (PCI) with stenting. However, a significant proportion of
      patients is considered clopidogrel resistant and this resistance is shown to be accompanied
      by future adverse events. The aim of the study is to define in consecutive patients with
      acute coronary syndrome (ACS) undergoing PCI, those aged&gt;75years and/or weighted&lt;60 Kg with
      high on-clopidogrel platelet reactivity (Platelet Reactivity Units-PRU≥235) as estimated 24
      hours post PCI with the VerifyNow assay. Those patients will be randomized after informed
      concent in 1:1 fashion to prasugrel 5 mg or clopidogrel 150mg daily. Platelet reactivity will
      be assessed at day 15 and then treatment crossover will be performed. At day 30 platelet
      reactivity will be determined as well.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>15 days</time_frame>
    <description>Platelet reactivity assessed with the VerifyNow assay at the end of each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyporesponsiveness rate (PRU≥235) at the end of the 2 treatment periods</measure>
    <time_frame>15 days</time_frame>
    <description>Hyporesponsiveness rate will be assessed 15 days after the onset of each study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Platelet Reactivity</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 150mg per day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 5mg for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150mg per day for 15 days</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 5mg per day for 15 days</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years old

          2. Patients having PCI with stenting 24 hours prior randomization, meeting the following
             criteria :

               -  Acute coronary syndrome (unstable angina or myocardial infarction)

               -  TIMI risk score&gt;2

          3. Platelet reactivity in PRU ≥235 24 hours post-PCI

          4. Age≥75 years and/or weight&lt;60 Kg

        4. Informed consent obtained in writing

        Exclusion Criteria:

          -  A history of bleeding diathesis

          -  Chronic oral anticoagulation treatment

          -  Contraindications to antiplatelet therapy

          -  Known platelet function disorders

          -  PCI or coronary artery bypass surgery &lt; 3 months

          -  Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; Thrombolysis in myocardial
             infarction flow 3)

          -  Planned staged PCI in the next 30 days

          -  Hemodynamic instability

          -  hemodialysis

          -  Creatinine clearance &lt;25 ml/min

          -  inability to give informed consent

          -  High likelihood of being unavailable for the Day 30

          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal
             bleeding within the previous 6 months.

          -  Other bleeding diathesis, or considered by investigator to be at high risk for
             bleeding on longterm antiplatelet therapy.

          -  Any previous history of ischemic stroke, transient ischemic attack, intracranial
             hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).

          -  Thrombocytopenia (&lt;100.000 / μL) at randomization

          -  Anaemia (Hct &lt;30%) at randomization

          -  Polycythaemia (Hct &gt; 52%) at randomization

          -  Periprocedural IIb/IIIa inhibitor administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Rio</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Platelet reactivity</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Prasugrel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

